Swiss pharmaceutical firm, Parsenn Products have announced plans for an intensive market entry programme for the Phytovir brand into Europe and Latin America.
At the same time the company is marking a decade since the launch of its topical cold sore brand – Phytovir – into Swiss pharmacies.
A natural remedy for the treatment of cold sores, Phytovir is clinically proven to be as effective as leading synthetic brands and renowned for its natural anti-viral and wound healing properties.
It is now available in a range of innovative formats, including cream, patches and lipsalve. As a herbal-based product Phytovir is also less likely to create viral resistance compared to synthetic products.
Since its launch in 1975, Parsenn Products has built a respected portfolio of consumer healthcare products into household names.
With widespread distribution across Switzerland and Germany, Parsenn Products have now announced plans for an intensive market entry programme for Phytovir into Europe and Latin America.
To facilitate this growth plan, Parsenn Products has partnered with healthcare specialists GBT Pharma.
Companies interested in bringing the Phytovir brand into their portfolio are invited to contact the GBT Pharma team at this exciting point in the project.